Search

Ali R Jazirehi

from Whittier, CA
Age ~56
Get Report
Connected to:
Ryan W Jaziri, 38Dan E Jazman, 38Dulce Jazmin, 46Juan C Jazmin, 37Norman Jazmyn, 40Ralph Jazon, 50Mourad Jazouli, 48Saba Jazrawi, 50Olena O Jazuk, 51Joseph J Jazwick, 61

Ali Jazirehi Phones & Addresses

  • 13568 Broadway, Whittier, CA 90601
  • Pasadena, CA
  • Brea, CA
  • 10840 Bellagio Rd, Los Angeles, CA 90077
  • 2059 Linnington Ave, Los Angeles, CA 90025

Work

Position: Sales Occupations

Education

Degree: High school graduate or higher

Publications

Us Patents

Molecular Signaling Pathways Triggered By Rituximab: Prognostic, Diagnostic, And Therapeutic Uses

View page
US Patent:
20090203050, Aug 13, 2009
Filed:
Nov 4, 2008
Appl. No.:
12/264812
Inventors:
Benjamin Bonavida - Los Angeles CA, US
Ali R. Jazirehi - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 31/7088
G01N 33/53
C12Q 1/68
US Classification:
435 723, 435 71, 435 6
Abstract:
The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-κB, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules.

Molecular Signaling Pathways Triggered By Rituximab: Prognostic, Diagnostic, And Therapeutic Uses

View page
US Patent:
20070172847, Jul 26, 2007
Filed:
Nov 15, 2006
Appl. No.:
11/560308
Inventors:
Benjamin Bonavida - Los Angeles CA, US
Ali Jazirehi - Los Angeles CA, US
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
C12Q 1/68
G01N 33/574
US Classification:
435006000, 435007230
Abstract:
The present invention provides markers associated with activated molecular signaling pathways (example: p38 MAKP, NF-κB, ERK1/2, YY-1 and AKT) inhibited by rituximab in cancer cells as well as pathways activated by rituximab (such as death receptors, RKIP, PTEN) all of which are associated with the regulation of chemo and immunoresistance. The present invention provides methods of prognosis and providing a prognosis for cancer such as lymphoma, leukemia, and autoimmune disease, as well as, methods of drug discovery. These markers are also therapeutic targets for treatment of cancer resistant to conventional and experimental cancer therapeutics. Inhibition or activation of expression and/or activity of targeted gene products sensitizes resistant tumor cells to subtoxic doses of cytotoxic treatment including chemotherapy, radiation therapy, or immunotherapy and gene therapy, and the cytotoxic molecules.
Control profile
Ali R Jazirehi from Whittier, CA, age ~56 Get Report